Fundraising FoxKIROMIC BIOPHARMA INC
Defunct1 known investors
Find your way into KIROMIC BIOPHARMA INC
Sign up to see every warm intro you have to KIROMIC BIOPHARMA INC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the KIROMIC BIOPHARMA INC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kiromic BioPharma was a clinical-stage biotherapeutics company using an AI-driven platform to develop allogeneic Gamma Delta T-cell immunotherapies for solid tumors, including lead candidate Deltacel-01 for lung cancer.
Investors · 1
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $850.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $226.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $222.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does KIROMIC BIOPHARMA INC do?
- Kiromic BioPharma was a clinical-stage biotherapeutics company using an AI-driven platform to develop allogeneic Gamma Delta T-cell immunotherapies for solid tumors, including lead candidate Deltacel-01 for lung cancer.
- Who are KIROMIC BIOPHARMA INC's investors?
- KIROMIC BIOPHARMA INC's investors include Sofinnova Ventures.